As of 2025-04-18, the EV/EBITDA ratio of Spero Therapeutics Inc (SPRO) is 0.15. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SPRO's latest enterprise value is -10.73 mil USD. SPRO's TTM EBITDA according to its financial statements is -72.42 mil USD. Dividing these 2 quantities gives us the above SPRO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.8x - 9.8x | 8.8x |
| Forward P/E multiples | 8.7x - 19.7x | 14.2x |
| Fair Price | (10.33) - (11.75) | (13.95) |
| Upside | -1469.0% - -1658.0% | -1950.0% |
| Date | EV/EBITDA |
| 2025-04-04 | 0.28 |
| 2025-04-03 | 0.25 |
| 2025-04-02 | 0.19 |
| 2025-04-01 | 0.19 |
| 2025-03-31 | 0.17 |
| 2025-03-28 | 0.14 |
| 2025-03-27 | 0.07 |
| 2025-03-26 | 0.04 |
| 2025-03-25 | 0.04 |
| 2025-03-24 | 0.10 |
| 2025-03-21 | 0.10 |
| 2025-03-20 | 0.13 |
| 2025-03-19 | 0.14 |
| 2025-03-18 | 0.15 |
| 2025-03-17 | 0.14 |
| 2025-03-14 | 0.13 |
| 2025-03-13 | 0.13 |
| 2025-03-12 | 0.15 |
| 2025-03-11 | 0.16 |
| 2025-03-10 | 0.15 |
| 2025-03-07 | 0.13 |
| 2025-03-06 | 0.12 |
| 2025-03-05 | 0.14 |
| 2025-03-04 | 0.14 |
| 2025-03-03 | 0.14 |
| 2025-02-28 | 0.13 |
| 2025-02-27 | 0.13 |
| 2025-02-26 | 0.12 |
| 2025-02-25 | 0.11 |
| 2025-02-24 | 0.11 |
| 2025-02-21 | 0.09 |
| 2025-02-20 | 0.08 |
| 2025-02-19 | 0.08 |
| 2025-02-18 | 0.10 |
| 2025-02-14 | 0.10 |
| 2025-02-13 | 0.10 |
| 2025-02-12 | 0.11 |
| 2025-02-11 | 0.10 |
| 2025-02-10 | 0.12 |
| 2025-02-07 | 0.10 |
| 2025-02-06 | 0.06 |
| 2025-02-05 | 0.05 |
| 2025-02-04 | 0.15 |
| 2025-02-03 | 0.11 |
| 2025-01-31 | 0.07 |
| 2025-01-30 | 0.06 |
| 2025-01-29 | 0.07 |
| 2025-01-28 | 0.06 |
| 2025-01-27 | 0.07 |
| 2025-01-24 | 0.06 |